title: Allogeneic hematopoietic SCT for patients with autoimmune diseases.
abstract: Allogeneic hematopoietic SCT (HSCT) has been used as treatment for single patients with autoimmune diseases (AD). To summarise currently available information, we analyzed all patients who underwent allogeneic HSCT for AD and who reported to the European Group for Blood and Marrow Transplantation (EBMT) database. Thirty-five patients receiving 38 allogeneic transplantations for various hematological and non-hematological AD were identified. Four patients had had an allogeneic HSCT for a conventional hematological indication in the past. Fifty-five per cent of the transplantation procedures led to a complete clinical response of the refractory AD and 23% to at least a partial response. The median duration of response at the last follow-up was 70.7 (15.2-130) months. Three patients relapsed at a median of 12.3 months after HSCT. Treatment-related mortality at 2 years was 22.1% (95% CI: 7.3-36.9%). Two deaths were caused by progression of AD. The probability of survival at 2 years was 70%. No single factor predicting the outcome could be identified. The retrospective nature of this study and the heterogeneous, partly incomplete data are its limitations. However, allogeneic HSCT can induce remission in patients suffering from refractory AD. These data provide the basis for carefully conducted prospective trials.
authors.affiliation: Department of Rheumatology, University of Basel, University Hospital, Basel CH-4031, Switzerland. tdaikeler@uhbs.ch
authors.forename: T
authors.initials: T
authors.lastname: Daikeler
authors.forename: T
authors.initials: T
authors.lastname: Hügle
authors.forename: D
authors.initials: D
authors.lastname: Farge
authors.forename: M
authors.initials: M
authors.lastname: Andolina
authors.forename: F
authors.initials: F
authors.lastname: Gualandi
authors.forename: H
authors.initials: H
authors.lastname: Baldomero
authors.forename: C
authors.initials: C
authors.lastname: Bocelli-Tyndall
authors.forename: M
authors.initials: M
authors.lastname: Brune
authors.forename: J H
authors.initials: JH
authors.lastname: Dalle
authors.forename: C
authors.initials: C
authors.lastname: Urban
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: B
authors.initials: B
authors.lastname: Gibson
authors.forename: B
authors.initials: B
authors.lastname: Linder
authors.forename: B
authors.initials: B
authors.lastname: Lioure
authors.forename: A
authors.initials: A
authors.lastname: Marmont
authors.forename: S
authors.initials: S
authors.lastname: Matthes-Martin
authors.forename: D
authors.initials: D
authors.lastname: Nachbaur
authors.forename: P
authors.initials: P
authors.lastname: Schuetz
authors.forename: A
authors.initials: A
authors.lastname: Tyndall
authors.forename: J M
authors.initials: JM
authors.lastname: van Laar
authors.forename: P
authors.initials: P
authors.lastname: Veys
authors.forename: R
authors.initials: R
authors.lastname: Saccardi
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
mesh_terms: D000293:Adolescent; D000328:Adult; D001327:Autoimmune Diseases / Q000401:mortality* / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D014184:Transplantation, Homologous